Literature DB >> 907239

Treated and untreated recurrent calcium nephrolithiasis in patients with idiopathic hypercalciuria, hyperuricosuria, or no metabolic disorder.

F L Coe.   

Abstract

Two hundred two recurrent calcium oxalate stone-forming patients with idiopathic hypercalciuria or hyperuricosuria, or both, were treated for an average of 2.91 years (1 to 7 years) with thiazide or allopurinol, or both. The frequency of new stone formation was drastically reduced. During the treatment period of 625 patient years, 220.0 new stones should have occurred, whereas 22 were actually formed (chi-square=178, P less than 0.001). Thirty-four patients without discernible metabolic disturbances and treated only with increased fluid intake and dietary advice formed 29 new stones compared to a predicted 33.2 stones (87.3%). Thirty similar patients treated with thiazide and allopurinol formed six stones compared to a predicted 31.8, P less than 0.001. Chronic reversal of idiopathic hypercalciuria and hyperuricosuria with thiazide and allopurinol is an effective way to prevent recurrent calcium oxalate stones. Conservative measures are only of marginal effectiveness in treating metabolically normal stone forming patients; however, thiazide and allopurinol appear to decrease new stone formation.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 907239     DOI: 10.7326/0003-4819-87-4-404

Source DB:  PubMed          Journal:  Ann Intern Med        ISSN: 0003-4819            Impact factor:   25.391


  45 in total

Review 1.  Pharmacotherapy of urolithiasis: evidence from clinical trials.

Authors:  Orson W Moe; Margaret S Pearle; Khashayar Sakhaee
Journal:  Kidney Int       Date:  2010-10-06       Impact factor: 10.612

2.  Inaccurate reporting of mineral composition by commercial stone analysis laboratories: implications for infection and metabolic stones.

Authors:  Amy E Krambeck; Naseem F Khan; Molly E Jackson; James E Lingeman; James A McAteer; James C Williams
Journal:  J Urol       Date:  2010-08-21       Impact factor: 7.450

Review 3.  Treatment of calcium nephrolithiasis in the patient with hyperuricosuria.

Authors:  Omotayo Arowojolu; David S Goldfarb
Journal:  J Nephrol       Date:  2014-04-01       Impact factor: 3.902

4.  Nephrocalcinosis in preterm babies.

Authors:  A Narendra; M P White; H A Rolton; Z I Alloub; G Wilkinson; J H McColl; J Beattie
Journal:  Arch Dis Child Fetal Neonatal Ed       Date:  2001-11       Impact factor: 5.747

5.  Renal stones and their medical management.

Authors:  E K Smith
Journal:  Can Fam Physician       Date:  1978-08       Impact factor: 3.275

6.  CUA guideline on the evaluation and medical management of the kidney stone patient - 2016 update.

Authors:  Marie Dion; Ghada Ankawi; Ben Chew; Ryan Paterson; Nabil Sultan; Patti Hoddinott; Hassan Razvi
Journal:  Can Urol Assoc J       Date:  2016-11-10       Impact factor: 1.862

7.  Urine glycoprotein crystal growth inhibitors. Evidence for a molecular abnormality in calcium oxalate nephrolithiasis.

Authors:  Y Nakagawa; V Abram; J H Parks; H S Lau; J K Kawooya; F L Coe
Journal:  J Clin Invest       Date:  1985-10       Impact factor: 14.808

8.  Thiazides in the prophylactic treatment of recurrent idiopathic kidney stones.

Authors:  J T Mortensen; A Schultz; A H Ostergaard
Journal:  Int Urol Nephrol       Date:  1986       Impact factor: 2.370

9.  Pathogenesis of bladder calculi in the presence of urinary stasis.

Authors:  M Adam Childs; Lance A Mynderse; Laureano J Rangel; Torrence M Wilson; James E Lingeman; Amy E Krambeck
Journal:  J Urol       Date:  2012-11-15       Impact factor: 7.450

Review 10.  New insights into the pathogenesis of idiopathic hypercalciuria.

Authors:  Elaine M Worcester; Fredric L Coe
Journal:  Semin Nephrol       Date:  2008-03       Impact factor: 5.299

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.